Come on in! The water's fine That's the general upshot of JPMorgan Chase 's latest upgrade  for shares of diabetes-drug maker MannKind ( NAS: MNKD ). With the sell-off after the firm's massive share issuance now over, and earnings out of the way as well, JP sounded the all-clear for investors Friday, and removed its sell rating on MannKind.